INBX Stock Forecast & Price Target

Inhibrx Biosciences Inc is positioned favorably due to its proprietary single-domain antibody and protein engineering discovery platform, which has the potential to generate significant value over the mid-to-long term. With a robust cash position of approximately $152.6 million, the company is well-equipped to advance its lead candidates, INBRX-109 and INBRX-106, towards critical clinical milestones expected in the latter half of 2025. Despite reporting a fourth-quarter EPS of ($3.09), which was below estimates, the anticipated cash balance of $73.2 million by the end of 4Q25 suggests a stable financial outlook for the company as it moves towards key readouts.

Inhibrx Biosciences is facing significant financial challenges, highlighted by revenues of only $100K in 4Q24, while research and development expenses reached $33.4MM, indicating heavy cash burn without substantial income. The company's selling, general, and administrative (SGA) expenses were $16.7MM, surpassing expectations and further straining financial resources, which could hinder future operational capabilities. Furthermore, the risks associated with clinical trials and the potential lack of competitive differentiation in their drug candidates may lead to delays in approvals or failures, adversely affecting Inhibrx’s long-term growth prospects and share price.